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Purpose: Heart failure is the ultimate complication of cardiac involvements in diabetes. The 
purpose of this review was to summarize current literature on heart failure among people with 
diabetes mellitus in sub-Saharan Africa (SSA).
Method: Bibliographic search of published data on heart failure and diabetes in sub-Saharan 
Africa over the past 26 years.
Results: Heart failure remains largely unexplored in general population and among people with 
diabetes in Africa. Heart failure accounts for over 30% of hospital admission in specialized 
cardiovascular units and 3%–7% in general internal medicine. Over 11% of adults with heart 
failure have diabetes. Risk factors for heart failure among those with diabetes include classical 
cardiovascular risk factors, without evidence of diabetes distinctiveness for other predictors 
common in Africa. Prevention, management, and outcomes of heart failure are less well known; 
recent data suggest improvement in the management of risk factors in clinical settings.
Conclusions: Diabetes mellitus is growing in SSA. Related cardiovascular diseases are emerg-
ing as potential health problem. Heart failure as cardiovascular complication remains largely 
unexplored. Efforts are needed through research to improve our knowledge of heart failure at 
large in Africa. Multilevel preventive measures, building on evidences from other parts of the 
world must go along side.
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Introduction
Diabetes mellitus, accounted for in major part by type 2 diabetes is increasing alarmingly 
in all parts of the world, including sub-Saharan Africa (SSA) (Wild et al 2004). According 
to the International Diabetes Federation (IDF) estimations, 246 millions people around 
the world suffer from diabetes in 2007. This ﬁ  gure will increase by 55% to reach 380 
million by the year 2025 (IDF 2006). Diabetes-related complications, led by cardiovascular 
complication (CVD) are already contributing a great deal to the global burden of disease 
(Roglic et al 2005). In General, up to 80% of deaths among people with diabetes occur 
thru CVD, and CVD account for 75% of hospital admission in diabetes. Numerous 
epidemiological studies are concordant over the fact that the risk of experiencing a CVD 
event in people with diabetes is two to four times greater than that among those without 
diabetes (Kannel and McGee 1979; Panzram 1987; Stamler et al 1993; APCSC 2003). 
While atherosclerotic vascular disease accounts for much of the cardiovascular morbidity 
and mortality among diabetic patients, congestive heart failure (CHF) is another key 
complication associated with diabetes, with an incidence that is two to ﬁ  ve times greater 
than that among individuals without diabetes (APCSC 2003). Once heart failure occurs, 
patients with diabetes have poorer prognosis than their nondiabetic counterparts.
Despite the growing importance of diabetes mellitus in SSA, evidence to support 
the related complications and particularly cardiovascular complications are still few. 
In a recent review, we have shown that although considered to be rare, CVD was on Vascular Health and Risk Management 2008:4(1) 124
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the rise among people with diabetes in SSA and was regularly 
associated with classical risk factors (Kengne et al 2005). 
However, individual cardiovascular complications and more 
precisely heart failure among people with diabetes in SSA 
are less well known. We aim in this review to summarize 
currently existing literature on heart failure in diabetes in 
SSA. Such information has relevance both for clinical and 
epidemiological purposes, given the rapidly changing pattern 
of disease occurrence in this part of the world.
Source of data
We searched MEDLINE® and reference lists of literature 
on heart failure and diabetes in SSA in June 2007. Initial 
MEDLINE search using the keys words “heart failure”, 
“diabetes”, and “Africa” provided 23 entries spanning 
from 1966 to 2006. This was considered inconsistent and 
an extended search using a combination of key words like 
“heart failure”, “cardiovascular disease”, “stroke”, and 
“Africa” without restriction to people with diabetes yielded 
1,245 entries extending from 1961 to 2007. Data search used 
in this review was limited to studies published after 1980. 
This cut-off was chosen because data collected before 1980 
may no longer reﬂ  ect the current situation of heart failure 
in SSA. The database obtained was contracted by eliminat-
ing duplicates, studies from Northern African countries, 
studies done on migrant Africans, case reports, and stud-
ies without heart failure or cardiovascular disease as main 
focus. The ﬁ  nal database consisted of 181 studies from a 
number of SSA countries, distributed over the 26 years, 
which is depicted by Figure 1. Some of these publications 
included multiple reports from the same studies. Literature 
from other parts of the world is used where relevant. The 
majority of articles were retrospective hospital-based studies 
in major urban cities that addressed aspects of heart failure 
and cardiovascular disease including incidence, types, risk 
factors, management, and outcomes. The data sources are 
mentioned wherever used in the text.
There are very limited published studies describing the 
burden of heart failure in SSA, most particularly among 
people with diabetes. Extrapolations from data published 
elsewhere have serious limitations. As new and better 
epidemiological data become available in the region, it will 
be possible to know the actual burden of heart failure in 
people with diabetes from this region.
Results and discussion
The burden of diabetes in Sub-Saharan 
Africa
The burden of diabetes in Africa has been presented in 
details elsewhere (Motala 2002; IDF 2006; Kengne and 
Mbanya 2006). The consistent theme is that the magnitude 
of diabetes mellitus and related health issues has not been 
reliably estimated for African countries. Extrapolation from 
existing point prevalence data suggest that 0.5% to 10% 
of adult population in Africa suffer from type 2 diabetes 
(Mbanya et al 2006). Plotting these ﬁ  gures on a time scale 
indicates that the prevalence of diabetes has increased by 
two- to ten-folds in both rural and urban settings in most 
African countries over the past two to three decades, (Mbanya 
et al 2006). The Diabetes Atlas provides some estimates and 
projections of diabetes ﬁ  gures for all its regions. In SSA, 
10.4 million individuals currently have diabetes, and projec-
tions by the IDF suggest that these ﬁ  gures will exceed 18.7 
million by 2025 (IDF 2006). Determinants of the growing 
prevalence of diabetes in Africa are similar to those reported 
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elsewhere. These include rapid urbanization, sedentary 
lifestyles, obesity, and unhealthy eating diets (Mbanya et al 
2006). Available prevalence studies are concordant over the 
fact that diabetes in Africa is 1.5 to 2 times more frequent in 
urban compared to rural areas. However, unpublished data 
from Cameroon suggest an attenuation of this rural–urban 
gradient with time.
Epidemiology of heart failure in Sub-
Saharan Africa
Heart failure is a major and growing public health problem 
on a global perspective. In spite of the scarcity of published 
literature on heart failure in SSA, the few available evidence 
suggest that the rate of hospital admission for heart failure 
is comparable with rates from the rest of the world, but the 
pathophysiology and etiologies are different (Mayosi 2007). 
Heart failure failure seems to be mainly due to systolic dys-
function and occurs as a major complication of high blood 
pressure in Africa and the ﬁ  rst cause of hospital admission 
among those with hypertension (Table 1) in cardiology units 
(Njoh 1990; Mensah et al 1994). In general internal medi-
cine services, heart failure has been described as the 5–6th 
cause of admission (Bardgett et al 2006). In Zimbabwe, 
while the proportion of hospital admission of patients with 
noncommunicable diseases has decreased over time, patients 
with heart failure have continued to contribute about 6% of 
hospital admission (Bardgett et al 2006). More importantly, 
over the same period, the proportion of death resulting from 
heart failure has signiﬁ  cantly increased.
The underlying process leading to heart failure in most 
developed countries is dominated by coronary heart disease 
(Mendez and Cowie 2001). In developing countries and most 
particularly those of SSA, nonischaemic causes of heart fail-
ure are dominant, with hypertensive heart disease, rheumatic 
heart disease, and cardiomyopathy accounting for over 75% 
of cases in most series (Amoah and Kallen 2000; Mendez 
and Cowie 2001). However, ischemic cardiomyopathies also 
seem to be growing in this setting (Table 2). That cardiac 
involvements in human immunodeficiency virus (HIV) 
infection, cor pulmonale, and pericarditis contribute to over 
20% of cases of heart failure in SSA reﬂ  ects the continu-
ing impact of HIV and tuberculosis on heart disease on the 
continent (Magula and Mayosi 2003; Mayosi et al 2005). 
Earlier reports from SSA highlight the major importance of 
rheumatic valvular diseases among causes of heart failure. 
However, recently published data favor hypertension as 
the dominant cause of heart failure in this part of the world 
(Mayosi 2007). Lessons from the changing epidemiology of 
heart failure in developed countries suggest that the burden 
of this disease will dramatically increase over the ﬁ  rst half 
of this century.
Compared to studies from other part of the world, heart 
failure in Africa tends to occur at a much younger age with 
most cases recorded around the 5th and 6th decade (Table 2). 
This young age reﬂ  ect the major contribution of rheumatic 
valvular disease to heart failure, but could also be accounted 
for by the early onset and severity of hypertension among 
Blacks. As reported elsewhere, most African studies have 
uniformly described a male predominance among those 
with heart failure in Africa (Table 2). Although heart failure 
management has beneﬁ  ted from major advances in the recent 
years, case fatality among people with heart failure remains 
high worldwide. Hospital case fatality among those with heart 
failure in Africa ranges from 9% to 12.5%. This consistent 
death rate ranks heart failure among the major causes of death 
of cardiovascular origin in Africa.
The clinical presentation of heart failure in Africa is 
characterized by the high proportion of symptomatic patients. 
More than 50% of patients present in stage III and IV of the 
NYHA classiﬁ  cation (Fofana et al 1988). Clinical signs and 
symptoms are similar to those reported elsewhere, but are 
dominated by the high prevalence of nonspeciﬁ  c features 
(Kingue et al 2005). Most clinical studies of heart failure 
in SSA were conducted in the pre-echocardiographic era or 
without the application of echocardiography. With recent 
echocardiographic studies, it is heartening to note that 
systolic dysfunction, a treatable and preventable form of 
heart failure is the most frequent cardiac dysfunction found 
(Kingue et al 2005). Most echocardiographic ﬁ  ndings are 
typical ﬁ  ndings expected for the various potential underlying 
aetiologies of heart failure. Three major trends emerge from 
few studies that have addressed the issue of management 
of heart failure in SSA: Firstly, underutilization of medica-
tions with proven efﬁ  cacy such as angiotensin-converting 
enzyme inhibitors (ACEI) and beta blockers. For example, 
in a study from Nigeria, only 65% of heart failure patients 
Table 1 Prevalence of heart failure among patients with hyper-
tension in selected African countries
Country  Year  Study   Prevalence of
   sample  heart  failure
Liberia (Njoh 1990)  1990  105  55.2%
Niger (Toure et al 1992)  1989  54  32.0%
Nigeria (Isezuo 2003)  2003  440  36.4%
Nigeria (Ayodele   2005  203  10.8%
et al 2005)Vascular Health and Risk Management 2008:4(1) 126
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were on ACEI (Adewole et al 1996). In another study from 
Cameroon, 19% of patients with heart failure were on beta 
blockers (Kingue et al 2005). Second, when medications 
are appropriately prescribed, this is not always followed 
by patient compliance (Bhagat and Mazayi-Mupanemunda 
2001). Finally, we were unable to identify reports of cardiac 
resynchronization therapy or ventricular assistant devices 
and heart transplantation, which are therapeutic options not 
yet accessible in most African countries.
Heart failure and diabetes in sub-Saharan 
Africa
Studies from other parts of the world suggest that up to 
25% of people with heart failure have diabetes (Bauters 
et al 2003). In the Heart Failure in Israel Survey (HFIS), up 
to 50% of patients admitted with heart failure had diabetes 
(Garty et al 2007). Diabetes mellitus has also been recog-
nized to play a key role in the pathogenesis, prognosis, and 
outcomes of heart failure (Solang et al 1999). Available data 
from Africa relate to prevalence of diabetes among those 
with heart failure in hospital retrospective review studies. 
In the study by Thiam and coworkers (2003) in Senegal, 
11.8% of heart failure patients had diabetes. In a study of 
572 consecutive patients with heart failure in Ghana, 17% 
of those with coronary artery disease had diabetes (Amoah 
and Kallen 2000). In a selective group of patients with heart 
failure in Nigeria, the proportion of those with diabetes was 
found to be 58% (Ola et al 2006). No study has so far directly 
compared the features of heart failure among people with and 
without diabetes in SSA.
Determinants of heart failure in diabetes 
in Africa
Many mechanisms exist to explain the high vulnerability 
of people with diabetes to heart failure. These include 
competing cardiovascular risk factors, diabetic speciﬁ  c 
cardiomyopathy, and other diabetes related risk factors, the 
accelerated coronary atherosclerosis in diabetes, and in the 
African setting, the potential interaction between diabetes and 
other risk factor for heart failure prevalent in SSA.
Classical cardiovascular risk factors
Available evidence supports the view that major cardio-
vascular risk factors affect the risk of future cardiovascular 
events in a similar way regardless of diabetes status (Kan-
nel and McGee 1979; Balkau et al 1993; Adlerberth et al 
1998). However, because most of these risk factors tend to 
cluster in people with diabetes, the resulting absolute risk 
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of experiencing a cardiovascular event will be much higher 
among people with diabetes compared with their nondiabetic 
counterparts (Stamler et al 1993). Major risk factors are also 
consistent across populations and include in addition to dia-
betes mellitus, age, hypertension and dyslipidemia, smoking, 
and male gender. Although outcomes studies relating the 
exposure to these factors to the risk of major cardiovascular 
events including heart failure are still lacking in SSA for both 
the general population and people with diabetes, it would be 
anticipated that the nature of this association will be similar 
to that reported in other parts of the world. However, the 
strength of the association may differ at least for some risk 
factors. For example, in the INTERHEART study, African 
participants with myocardial infarction were signiﬁ  cantly 
younger compared with participants from other parts of the 
world (Steyn et al 2005). Similarly, when most of the classi-
cal risk factors are considered on their absolute levels, people 
with diabetes from Africa tend to display different proﬁ  les. 
For instance, the age at onset of type 2 diabetes in Africa is 
much younger, while people with diabetes from Africa tend 
to display high prevalence of hypertension (Choukem et al 
2007) and prevalence of dyslipidemia, and smoking habits 
are still low among Africans in general.
Diabetes-related risk factors
Chronic hyperglycemia, insulin resistance and accumulation 
of collagen and other glycation end-products in the myocar-
dium of people with diabetes are believed to be associated 
with pathological changes at the level of cardiac myocytes 
that ultimately result in diabetic cardiomyopathy with 
increased myocardial stiffness and early abnormal diastolic 
function. Diabetic cardiomyopathy is characterized by defects 
of left ventricular function in the absence of signiﬁ  cant CAD 
or systemic hypertension (Bell 1995, 2003). The condition 
is associated with important clinical consequences, such as 
increased susceptibility to hypertension-mediated damage, an 
increased mortality rate after acute myocardial infarction and 
progression to symptomatic heart failure (Factor et al 1980; 
Jaffe et al 1984). In addition to diabetic cardiomyopathy, 
left ventricular hypertrophy and systolic dysfunction that is 
often asymptomatic and may lead to congestive heart failure 
have been described in African diabetic patients. Indeed up 
to 50% of asymptomatic diabetic patients may present with 
echocardiographic abnormalities (Babalola and Ajayi 1992). 
However, appropriate comparison of ventricular indexes with 
matched background nondiabetic population is still lacking. 
In one of the earliest study of infra-clinical alterations of the 
left ventricular functions, Famuyiwa and co-workers (1985) 
compared 89 participants with diabetes with 45 nondiabetic 
controls, and reached the conclusion that people with diabetes 
were less vulnerable to vascular complications. However, this 
study has been contradicted by most recent reports both from 
Nigeria and elsewhere (Mbanya et al 2001; Danbauchi et al 
2005). In a study from Cameroon, Mbanya and his colleagues 
(Mbanya et al 2001) found a 40% and 55% prevalence of left 
ventricular hypertrophy and systolic dysfunction among their 
selective sample of 40 patients with diabetes. This was in 
keeping with another study from Nigeria in which Danbauchi 
and his team reported signiﬁ  cant sub-clinical cardiomyopathy 
in people with diabetes (Danbauchi et al 2005). In another 
recent study among population with hypertension in South 
Africa, the prevalence of LVH was not different between 
those with and without type 2 diabetes. In addition, diabetes 
in this study was not an independent predictor of LVH in 
multivariate analysis (Rayner and Becker 2006). In the midst 
of these inconsistencies, cardiomyopathy among people with 
diabetes in Africa deserves further attention, both to clarify 
the existence and explore underlying pathophysiologic 
derangements.
Other contributors
Underlying causes of heart failure vary consistently across 
regions in the world. In SSA, hypertension, valvular heart dis-
eases, and various cardiomyopathies are the dominant causes 
among adults (Sliwa et al 2005; Commerford and Mayosi 
2006; Opie 2006). One question is whether there is any 
interaction between diabetes and other determinants of heart 
failure mostly found in Africa. In the ﬁ  rst analysis, it could be 
envisaged that diabetes would act at least as a co-factor and 
may further accelerate the onset of heart failure in patients 
who are cumulating other risk factors. A controversial role of 
diabetes as independent risk factor for nonrheumatic valvular 
disease has been described elsewhere, but not yet in Africa 
(Movahed et al 2007). However, if conﬁ  rmed in addition to 
rheumatic heart disease, already common in Africa, a greater 
contribution of valvular disease to heart failure would be 
expected in Africa in the context of the growing burden of 
diabetes. Anemia, a common ﬁ  nding in individuals with 
diabetes and particularly those with kidney involvement, may 
precipitate the unset or exacerbate the already established 
heart failure in this category of patients. In Africa, even 
among those without diabetes, anemia is already frequent 
as a result of infectious diseases and nutritional deﬁ  ciencies 
(Ladipo 1981). Heart failure is rare among pregnant women 
in Africa and is most often the consequence of valvular 
heart diseases (Abengowe et al 1980; Aggarwal 1980). Vascular Health and Risk Management 2008:4(1) 128
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The congestive phase tends to occur more in the postpartum 
period and the incidence is not affected by parity and 
socioeconomic class (Abengowe et al 1980). As a contribu-
tor, diabetes has not yet been reported.
Management of heart failure in diabetes
The long-term care of diabetic patients with heart disease 
poses a particular challenge. Various combinations of risk 
factors, progression of the coronary heart disease, and com-
plications with further organic damage by the underlying 
diabetes frequently necessitate a differentiated diagnostic 
work-up and management.
Control of cardiovascular and diabetes-related risk 
factors
Compelling evidence from cardiovascular outcomes tri-
als indicates that treatment with drugs that block the 
rennin – angiotensin system are cardioprotective in diabetics 
with microalbuminuria and early stages of kidney disease. 
Multiple risk factor intervention aimed at optimal blood 
pressure control, lowering LDL cholesterol and triglyceride 
levels, treatment with an ACEI or an angiotensin II receptor 
blocker, administration of once daily low-dose aspirin and 
smoking cessation together reduce cardiovascular morbidity 
and mortality in type 2 diabetics. Since there is epidemiologic 
evidence of a relationship between poor metabolic control 
and development of heart failure (Iribarren et al 2001), it 
would be interesting to evaluate whether aggressive treatment 
addressing the metabolic consequences of diabetes would 
improve outcome in diabetic patients with heart failure. 
However, data on glucose control and heart failure are rare 
and inconclusive (Tang 2006). This is partly due to the lack 
of trials targeting speciﬁ  cally those with diabetes and heart 
failure, but also to the poor understanding of the pathophysi-
ologic derangements linking diabetes to heart failure.
Medical treatment of heart failure
Standard medical treatments applied for heart failure in 
population without diabetes are associated with at least 
similar beneﬁ  cial impact in those with diabetes. There remain 
however some uncertainties about the safety of current anti-
diabetic medications when used in people with heart failure 
(Fisman et al 2004; Skouri and Wilson Tang 2007). In addi-
tion, agents of the thiazolidinedione class may be associated 
with increased risk of heart failure in people with diabetes 
(Lincoff et al 2007; Singh et al 2007). These medications 
however are likely to be infrequently used in SSA. Despite 
the concerns about adverse metabolic effect of beta blockers, 
available evidence support the view that beta blockers and 
particularly the nonselective vasodilating ones like carvedilol 
confer similar survival beneﬁ  t in heart failure patients with 
and without diabetes (Bell et al 2006). Subgroup analyses 
from large clinical studies have shown that ACEIs not only 
reduce mortality in diabetic patients with heart failure, but 
also reduce the incidence of heart failure in at-risk diabetic 
patients (Vermes et al 2003).
Cardiac resynchronization therapy and implantable 
cardioverter-deﬁ  brillators
Several trials have shown that cardiac resynchronization 
therapy (CRT) improves symptoms in patients with advanced 
heart failure and wide QRS complexes who remain symp-
tomatic in spite of optimal medical therapy (Bradley et al 
2003). Comparison of effectiveness of CRT in patients with 
and without diabetes mellitus shows that the beneﬁ  t of CRT 
is similar in both groups (Kies et al 2005). While ICD do 
not improve functional outcomes, they do provide substan-
tial mortality beneﬁ  ts by preventing sudden cardiac death in 
patients with heart failure who have an ischemic substrate, 
poor ejection fraction, and history of ventricular arrhythmias. 
To our knowledge, no study in SSA has reported results of 
these novel therapies of heart failure.
Revascularization
Diabetic patients are known to have reduced long-term 
survival following percutaneous transluminal coronary 
angioplasty compared with nondiabetic patients. This survival 
disadvantage has persisted over time and can at least in part 
be explained by the high prevalence of comorbidities among 
people with diabetes (Mathew et al 2004; Wilson et al 2004). 
There are also some controversies regarding the worse post-
procedure outcome in insulin-treated patients compared with 
those on diet or oral agents (Mathew et al 2004). However, 
a difference in the outcome if any should be interpreted in 
the light of the severity of diabetes and related vascular 
involvements in insulin-treated type 2 diabetic patients.
Heart transplantation
Heart transplantation is the most indicated treatment for 
end-stage heart failure, but its impact is limited by the 
scarcity of donor organs and stringent selection criteria 
for both donors and recipients. For example, the presence 
of diabetes complications in the past has limited this 
approach in people with diabetes. Few data are available 
to suggest that long-term survival in people with diabetes 
and diabetes related complications compare to that among 
their counterparts without complications (Morgan et al Vascular Health and Risk Management 2008:4(1) 129
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2004; Felker et al 2005; Ikeda et al 2007). However, post 
transplant follow-up face with important diabetogenic effects 
of classical immunosuppressive drugs. Even when indicated, 
this treatment option is not widely available in SSA.
Conclusions
One of the earliest documented clinical observations of the 
syndrome of heart failure originates from Africa (Saba et al 
2006). Surprisingly, this disease entity has remained largely 
unexplored in this part of the world and particularly among 
the highly vulnerable population with diabetes mellitus. In 
the general internal medicine service in urban settings, heart 
failure account for more than 3% of hospital admission, and 
over 30% among those admitted for cardiovascular diseases. 
Hypertension, valvular heart diseases, and cardiomyopathies 
are the main providers of heart failure in SSA, accounting 
for over 75% of cases in most series. The contribution of 
diabetes is still ill-studied. However, more than 10% of adults 
with heart failure also have diabetes. Determinants of heart 
failure reported elsewhere in people with diabetes are also 
found among people with diabetes in Africa, but, there are 
still some inconsistencies about the contribution of diabetic 
cardiomyopathy. The available pharmacological treatments, 
such as ACEIs, beta-blockers, and possibly angiotensin 
receptor blockers, together with a tight glycemic control, as 
reported elsewhere, must be effective for the treatment of 
heart failure if adequately used among people with diabetes 
in Africa.
There is need for more elaborate studies of heart failure in 
the general population in Africa and in people with diabetes 
in particular, given their high vulnerability. It is expected that 
initiatives such as The Heart of Soweto Study (Stewart et al 
2006) will provide a body of information on heart diseases 
and therefore heart failure as observed in SSA communities. 
There is evidence in support of the existing and growing 
capacity for research on chronic and cardiovascular diseases 
in SSA (Hofman et al 2006). If encouraged and provided 
with the needed support, their efforts are likely to translate 
into more insight into heart failure and other cardiovascular 
diseases in countries of this region.
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